anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Of the total number of subjects in clinical studies of ceftriaxone sodium, 32% were 60 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Ceftriaxone is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

The pharmacokinetics of ceftriaxone were only minimally altered in geriatric patients compared to healthy adult subjects and dosage adjustments are not necessary for geriatric patients with ceftriaxone dosages up to 2 grams per day, provided there is no severe renal and hepatic impairment. [see Clinical Pharmacology (12)]
People with schizophrenia often lead more sedentary lifestyles than people without the disease, and they are frequently treated with antipsychotic medications that cause weight gain. Combined, these factors produce an increased risk for metabolic syndrome, which can lead to heart disease and type 2 diabetes. Characteristics of metabolic syndrome include carrying excess weight around the abdominal region; high blood pressure; high blood sugar levels; high levels of fat in the blood; and low levels of HDL cholesterol. Recent studies have shown that certain atypical antipsychotic drugs are relatively weight-neutral. Switching from a drug that promotes weight gain to a weight-neutral medication, such as ziprasidone, may result in significant weight loss. There is insufficient evidence, however, demonstrating the extent of improvement in insulin sensitivity after switching medications. This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with schizophrenia who are at risk for diabetes.

Participants in this open label study will currently be undergoing treatment with risperidone or olanzapine at the time of study entry. Upon study entry, they will be randomly assigned to either switch to ziprasidone treatment or remain on their current medications. Both groups will be treated for 26 weeks. Participants will report to the study site for evaluations biweekly until week 10 and then monthly for the duration of the study. The primary outcomes at Week 26 will be: change from baseline in insulin sensitivity, using an intravenous glucose tolerance test; change from baseline in ivisceral fat mass, using a CT scan.
Treatment sequence EDACB is applied. The 5 treatments were separated by a washout period of at least 5 days.
PURPOSE OF REVIEW: Thirty-day mortality (30DM) is an emerging consideration for determining whether terminally ill adult patients may benefit from palliative radiotherapy (RT). However, the efficacy and ethics of delivering palliative RT at the end of life (EOL) in children are seldom discussed and not well-established.
RECENT FINDINGS: Palliative RT is perhaps underutilized among patients ≤21 years old with rates as low as 11%. While effective when delivered early, clinical benefit decreases when administered within the last 30 days of life. Pediatric 30DM rates vary widely between institutions (0.7-30%), highlighting the need for standardized practices. Accurate prognosis estimation remains challenging and prognostic models specific to palliative pediatric patients are limited. Discordance between provider and patient/parent perceptions of prognosis further complicates decision-making.
SUMMARY: RT offers effective symptom control in pediatric patients when administered early. However, delivering RT within the last 30 days of life may provide limited clinical benefit and hinder optimal EOL planning and care. Early referral for palliative RT, preferably with fewer fractions (five or fewer), along with multidisciplinary supportive care, optimizes the likelihood of maintaining patients' quality of life. Prognosis estimation remains difficult, and improving patient and family understanding is crucial. Further research is needed to refine prognostic models and enhance patient-centered care.
The invention discloses design synthesis of a near-infrared aggregation-induced emission material with strong two-photon absorption, organelle imaging and photodynamic therapy application thereof. Through reasonable molecular structure design, four near-infrared aggregation-induced emission materials with large two-photon absorption cross sections and high brightness are obtained. These materials have large stokes shifts, good biocompatibility, and excellent photostability. Three of the neutral materials can specifically image lipid droplets, and the other cationic material can specifically image mitochondria. These four materials can be used for two-photon fluorescence imaging of cells and living tissues in view of their excellent two-photon properties. The four materials can effectively generate singlet oxygen under illumination, so that the materials can be used for targeted photodynamic therapy of two-photon excited organelles. The material synthesized by the invention shows the property of aggregation-induced emission, and effectively overcomes the defects of the traditional fluorescent dye.
EA women are also at disproportionate risk for psychological dysregulation. EAs experience the highest rates of perceived stress relative to any other age group, with EA women experiencing intersectional stress related to multiple aspects of their identity (e.g., gender, race, ethnicity, body size), coupled with life stressors unique to emerging adulthood. Further, prevalence of major depressive episodes is highest among 18-25-year-olds relative to other age groups, and higher among women than men. Our preliminary data suggest exposure to life events, insufficient sleep, depressive symptoms, and perceived stress interfere with weight loss treatment benefit in EAs. This blunted treatment response is not due to insufficient engagement in self-monitoring behaviors; rather, we posit that the cognitive processing required for effective self-regulation is disrupted by inflammatory cytokine activity. Extant behavioral weight loss programs are insufficient to address underlying behavioral/psychological dysregulation, and do not promote behavior change through the lens of inflammation. Thus, a new model is needed to optimize clinical impact in this high-risk population.
PURPOSE:To make possible the quantitative determination of the antigen or antibody which is the intended trace component in a sample with high sensitivity in a short analyzing period by incorporating a compd. which emits the time- divided fluorescence as an index into a microcapsule conjugated with the antigen or antibody. CONSTITUTION:An animal membrane, for example, the red blood cells of goat are used as the microcapsule which can conjugate the antigen or antibody. The red blood cells of other animals or animal cells in addition to the red blood cells or even liposome which are the artificial membrane are used by conjugating the antibody or antigen to the membrane. Any material can be used as the microcapsule if the microcapsule can contain the compd. emitting the time-divided fluorescence as the index. The method for conjugating the antigen or antibody to the membrane permits the conjugation of an antigen or antibody by adsorption therewith if the membrane is the animal membrane and permits the conjugation of the antigen or antibody with the membrane by forming, for example, a carboxyl group to the membrane if the membrane is the artificial membrane.
BACKGROUND: The presence of coronary plaques with high-risk characteristics is strongly associated with adverse cardiac events beyond the identification of coronary stenosis. Testing by coronary computed tomography angiography (CCTA) enables the identification of high-risk plaques (HRP). Referral for CCTA is presently based on pre-test probability estimates including clinical risk factors (CRFs); however, proteomics and/or genetic information could potentially improve patient selection for CCTA and, hence, identification of HRP. We aimed to (1) identify proteomic and genetic features associated with HRP presence and (2) investigate the effect of combining CRFs, proteomics, and genetics to predict HRP presence.
METHODS: Consecutive chest pain patients (n = 1462) undergoing CCTA to diagnose obstructive coronary artery disease (CAD) were included. Coronary plaques were assessed using a semi-automatic plaque analysis tool. Measurements of 368 circulating proteins were obtained with targeted Olink panels, and DNA genotyping was performed in all patients. Imputed genetic variants were used to compute a multi-trait multi-ancestry genome-wide polygenic score (GPSMult). HRP presence was defined as plaques with two or more high-risk characteristics (low attenuation, spotty calcification, positive remodeling, and napkin ring sign). Prediction of HRP presence was performed using the glmnet algorithm with repeated fivefold cross-validation, using CRFs, proteomics, and GPSMult as input features.
RESULTS: HRPs were detected in 165 (11%) patients, and 15 input features were associated with HRP presence. Prediction of HRP presence based on CRFs yielded a mean area under the receiver operating curve (AUC) ± standard error of 73.2 ± 0.1, versus 69.0 ± 0.1 for proteomics and 60.1 ± 0.1 for GPSMult. Combining CRFs with GPSMult increased prediction accuracy (AUC 74.8 ± 0.1 (P = 0.004)), while the inclusion of proteomics provided no significant improvement to either the CRF (AUC 73.2 ± 0.1, P = 1.00) or the CRF + GPSMult (AUC 74.6 ± 0.1, P = 1.00) models, respectively.
CONCLUSIONS: In patients with suspected CAD, incorporating genetic data with either clinical or proteomic data improves the prediction of high-risk plaque presence.
TRIAL REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT02264717 (September 2014).
PROBLEM TO BE SOLVED: To obtain the subject skin preparation for external use capable of imparting a barrier layer for irritant materials different in water solubility, oil solubility, etc., to the outermost surface of skin and effective in improving roughened skin by including plural polymers capable of mutually forming percolation structures when formed into a film. SOLUTION: This skin preparation for external use is obtained by including two or more kinds of polymers capable of mutually forming percolation structures when formed into a film (a modulated structure in spinodal decomposition in phase-separation behavior between incompatible different kinds of polymers), e.g. (A) a polymer having <7.5×10-6 m3 (STP) m/m2.s.kPa water vapor transmission coefficient (e.g. pullulan) and (B) a polymer having >=7.5×10-6 m3 (STP) m/m2.s.kPa water vapor transmission coefficient (e.g. polyethylene glycol). The formulation ratio of the ingredients is preferably (10/90) to (90/10) of the ingredients A and B expressed in terms of weight ratio and the total amount of the ingredients A and B is preferably 0.001-60 wt.% in the total composition.
All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8011.
National surveillance data were collected to study the outbreak trends of infectious diseases/syndromes before and during the COVID-19 pandemic period, spanning from 2018 to 2022. The study found that out of 4208 outbreaks, 2972 occurred before the COVID-19 period, affecting 147,425 people, while 1236 outbreaks affected 52,324 people during the pandemic. The number of outbreaks for diseases such as acute flaccid paralysis, fever with rashes, leptospirosis, rabies, and scrub typhus increased during the pandemic. The geographic distribution of outbreaks remained similar for some reemerging diseases in both periods. The trends for dengue, Japanese encephalitis, and cholera remained consistent with peaks mostly from July to September in both periods. We observed a considerable reduction in morbidity and mortality due to outbreaks in India during the pandemic. Despite similar distributional patterns, the study indicates a strong suspicion of persistent outbreak-initiating factors, necessitating an efficient and vigilant surveillance system in the country.
The objectives of this study were to identify factors associated with the relative change in prepartum DMI (RCDMI) of 273 cows fed individually, evaluate the performance of linear models to estimate RCDMI using different classes of predictors, and characterize the implications of RCDMI to transition metabolism, health, and subsequent milk production. Two periods of interest were established. Period 1 comprised d -21 to -12 relative to calving, when DMI was stable. Period 2 comprised d -4 to -1, when average DMI was distinctly declined. The RCDMI from period 1 to 2 was calculated as a percentage value, which ranged from -75% to 15% and averaged -18.1% (± 15.0%). Season, parity, body fatness, body weight, milk production in the previous lactation and at dry-off, and length of dry period were associated with RCDMI and explained 11% of the variation in all cows, and 19% when only parous cows were considered. Performance of linear models to predict RCDMI was improved when data on rumination and physical activities and target blood metabolites were added. The adjusted R2 increased to values between 0.45 and 0.55, and selected models performed consistently in cross-validation analyses. To evaluate the implications of RCDMI, cows were ranked within parity according to RCDMI and classified into terciles as large decline (LDec), moderate decline (MDec), or small decline (SDec). By design, DMI did not differ between tercile groups in period 1 (13.3 ± 0.2 kg/d), but differed substantially in period 2 (LDec = 8.8; MDec = 11.2; SDec = 12.7 ± 0.2 kg/d), creating important differences in RCDMI among groups (LDec = -33.8; MDec = -16.2; SDec = -3.4% ± 0.8%). At enrollment, cows in the LDec and MDec groups were heavier (LDec = 788; MDec = 775; SDec = 750 ± 7 kg), and the proportion of cows with BCS >3.5 was higher in LDec (LDec = 63%; MDec = 47%; SDec = 38%). An interaction between group and time was observed for postpartum DMI, which started lower in LDec than in SDec cows, equaled by the end of transition, and inverted at wk 13 and 14 after calving. Yields of ECM were greater in LDec than in SDec cows, and both groups did not differ from MDec (LDec = 41.0; MDec = 40.3; SDec = 39.0 ± 0.5 kg/d). The LDec cows had decreased energy balance and greater concentrations of nonesterified fatty acids, β-hydroxybutyrate, and aspartate aminotransferase in serum, and greater glutathione peroxidase activity in plasma than SDec cows. Larger declines in prepartum DMI were also associated with increased risk for postpartum disease, although the associations were only weak to moderate. In conclusion, a large decline in prepartum DMI of cows fed ad libitum was associated with important adjustments in the energy metabolism and antioxidants activities, and greater milk production in the subsequent lactation. These findings indicate that feed intake decline close to parturition is likely a normal response to physiological adaptations at the onset of lactation when cows are fed ad libitum.
This study implements a 14-week home-based rehabilitation program for older adults after hip fractures. Participants will receive 8 home visits by a Physiotherapist (PT) and/or Physio assistant(PTA), focusing on individualized exercise programs and pain self-management. The intervention aims to improve functional recovery and includes PT-led assessments, exercise adjustments, and discharge assessments. PTAs support exercise delivery and education. The clinical team comprises PTs and PTAs, receiving training on exercise principles, pain education, and goal setting. The program emphasizes progressive strengthening, balance, and functional exercises, adhering to evidence-based principles. The intervention aims to enhance efficiency, reduce wait times, and promote adherence.
PURPOSE: Various medications are administered to treat Coronavirus Disease 2019 (COVID-19) infection and prevent its complications. Some medicines have complications and long-term effects, which may mimic other conditions, making precise diagnosis difficult. This report aims to bring to light one such complication, medication-related osteonecrosis of the jaw (MRONJ), secondary to a commonly prescribed medication for preventing lung fibrosis post-COVID-19 infection.
METHOD: A 33-year-old male reported to our department with the typical clinical and radiological features of Mucormycosis of the upper jaw post-COVID-19 infection. However, on detailed evaluation of his history (controlled diabetic and short duration of steroid therapy) and review of the mycology staining, bacteriology, culture, and histopathological reports, we came to a negative diagnosis for Mucormycosis. The patient was, however, on treatment for the prevention of lung fibrosis with Nintedanib (tyrosine kinase inhibitor) 150 mg twice a day for one month.
RESULT: In the absence of predisposing factors and negative laboratory findings for mucormycosis, we arrived at a diagnosis of MRONJ, attributable to Nintedanib therapy given to prevent lung fibrosis post-COVID-19 infection.
CONCLUSION: The use of Nintedanib has recently increased due to the high incidence of lung fibrosis post-COVID-19 infection. However, Nintedanib should be considered a causative agent for osteonecrosis of the jaw in the absence of other obvious predisposing factors. Therefore, Nintedanib must be administered after a thorough consideration of risk factors.
BACKGROUND: Recent studies have demonstrated that accelerated enhanced recovery after colorectal surgery is feasible for specific patient populations. The accelerated enhanced recovery protocols (ERP) tend to vary, and the majority of studies included a small study population. This hampers defining the optimal protocol and establishing the potential benefits. This systematic review aimed to determine the effect of accelerated ERPs with intended discharge within one day after surgery.
METHODS: PubMed (MEDLINE), Embase, Cochrane and Web of Science databases were searched using the following search terms: colon cancer, colon surgery, accelerated recovery, fast track recovery, enhanced recovery after surgery. Clinical trials published between January 2005 - February 2023, written in English or Dutch comparing accelerated ERPs to Enhanced Recovery After Surgery (ERAS) care for adult patients undergoing elective laparoscopic or robotic surgery for colon cancer were eligible for inclusion.
RESULTS: Thirteen studies, including one RCT were included. Accelerated ERPs after colorectal surgery was possible as LOS was shorter; 14 h to 3.4 days, and complication rate varied from 0-35.7% and readmission rate was 0-17% in the accelerated ERP groups. Risk of bias was serious or critical in most of the included studies.
CONCLUSIONS: Accelerated ERPs may not yet be considered the new standard of care as the current data is heterogenous, and data on important outcome measures is scarce. Nonetheless, the decreased LOS suggests that accelerated recovery is possible for selected patients. In addition, the complication and readmission rates were comparable to ERAS care, suggesting that accelerated recovery could be safe.
PROBLEM TO BE SOLVED: To obtain the subject medicine capable of inhibiting collagen synthesis and treating morbid state of accentuation of cell matrix production by including a pyranopyranone compound as an active ingredient. SOLUTION: This medicine has a compound of formula I [R' is a hexose residue obtained by eliminating OH at 1 position of hexose; R<a> is a group of formula II (R<b> is H, an alkyl, etc.; R<c> and R<d> are each H, an amino-protecting group or R<c> and R<d> together form trimethylene, etc.) or H]. The compound of, formula I includes swertiamarin which is obtained by extracting swertia Herb which is a crude medicine. The medicine has action improving accentuation of collagen synthesis observed in cells attacked by diseases exhibiting morbid state of accentuation of extracellular matrix production, e.g. liver cirrhosis, interstitial lung disease, chfonic renal failure, cardiac hypertrophy, postoperative cicatrix, burn cicatrix, keloid or hypertrophic cicatrix caused after traffic accident, scleroderma, arteriosclerosis or rheumatoid arthritis and effectively can treat the above diseases.
Stereotactic Body Radiation Therapy (SBRT) followed by prostatectomy and Quality of Life questionnaires. The radiation will be given for only 5 days. Conventional radiation to the prostate is given over 7-8 weeks.
PURPOSE:To obtain a saccharide-containing antitumor agent showing strong multiplication inhibition activity against tumor cell consisting essentially of protein substance fractionated from a culture solution of Actinomyces Streptomyces hachijoensis. CONSTITUTION:Streptomyces hachijoensis is cultivated by a well-known method and a crude fraction containing the aimed substance is obtained from the culture solution. Then the crude fraction is treated by precipitation with ammonium sulfate to give a protein fraction. Further, protein fraction is collected by zone electrophoresis, purified, dialyzed and lyophilized to give a novel protein substance of light yellow powder. The protein has 20000-60000 molecular weight measured by SDS-polyacrylamide gel electrophoresis and 5.0-7.0 isoelectric point. A saccharide-containing antitumor agent consisting essentially of the protein is prepared.
Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides derived from the SEMA5B gene that elicit CTLs and thus are suitable for use in the context of cancer immunotherapy are provided. The inventive peptides encompass both SEMA5B-derived peptides and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding such peptides as well as pharmaceutical compositions that include any such peptides or polynucleotides as active agents. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors) such as esophageal cancer, NSCLC, RCC and SCLC, and/or the prevention of a metastatic or postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from SEMA5B, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.